Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows

Lynparza Maintenance Delays Progression in Ovarian Cancer Patients by 3 Years, Phase 3 Trial Shows
Ovarian cancer patients with BRCA mutations who received Lynparza (olaparib) maintenance treatment after first-line platinum-based chemotherapy lived three years longer without signs of disease worsening than patients who received a placebo, data from a Phase 3 trial shows. Trial results, “Olaparib maintenance therapy following first-line platinum-based chemotherapy in patients with FIGO stage III–IV ovarian cancer (OC) with a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial,” were presented by Kathleen Moore, MD, on Oct. 21 at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich. Findings were also published in the study, "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer," in The New England Journal of Medicine on the same day. “The median PFS for patients who received placebo was only 13.8 months while the median PFS for those who received olaparib was not reached but looks to be approximately three years longer than the placebo group,” Moore, who is an associate professor at the Stephenson Cancer Center, University of Oklahoma, said in a
Subscribe or to access all post and page content.